Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection, in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin.
Fennec recently announced the initiation of two other institution-led clinical studies. Additional investigator-initiated studies supporting the use of PEDMARK have been submitted to Fennec and are currently under review.
In a statement, Pierre S. Sayad, PhD, MS, CMO of Fennec, commented, “At Fennec, we are committed to supporting independent research efforts, which help build real-world evidence and expand understanding of how PEDMARK may benefit patients beyond the populations studied in our pivotal trials. Within the last few months, we have announced the initiation of three new studies with leading and highly respected academic and community oncology centers. We believe that data and insights generated through these studies – and others to come – will help support broader clinical adoption of PEDMARK to prevent ototoxicity, or permanent hearing loss, in AYA and adult cancer patients receiving cisplatin-based treatment. We look forward to continued dialogue with regulatory authorities regarding the potential pathways for PEDMARK label expansion as our growing body of evidence-based data matures.”
